N/A N=166 Evaluation of an Incentive-based Intervention to Improve 90-day Adherence in PAP-Naive Patients
Obstructive Sleep Apnea
Primary: Mean PAP Usage at 90 Days — 4.67; 4.59 hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants
Healthy
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of Galcanezumab — 12.6; 27.2 micrograms per milliliter (μg/mL)
Phase 3 N=571 Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
Migraine
Primary: Mean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity During the 12-week Period After the First Dose of…
N/A N=909 STAMP: Sharing and Talking About My Preferences
Advanced Care Planning (ACP)
Primary: Number of Participants Who Completed Four ACP Activities: Communication With Loved Ones About Quality Versus Quantity of Life, Completion of a Living Will, Assignment of…
Phase 4 N=70 Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Negative Symptoms as Measured by the Scale for the Assessment of Negative Symptoms (SANS) Total Score — 33.1; 34.1; 34.1; 32.8 score on a scale
Phase 2 N=733 A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
COPD · Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in FEV1 AUC(0-12h) Normalized by Time at Week 6 — 0.070; 0.118; 0.153; 0.147 Litres — p=0.037
Phase 2 N=113 Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
Type 2 Diabetes Mellitus
Primary: Change in HbA1c in Subjects With Type 2 DM — -0.25; -1.47 mmols/mol
Phase 3 N=867 An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
Advanced Solid Malignancies
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) — 265; 300; 97; 21 participants
Phase 3 N=609 A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors
Ulcerative Colitis
Primary: Induction Phase: Percentage of Participants With Remission at Week 14, as Determined by the Mayo Clinic Score (MCS) — 6.3; 18.5 Percentage of Participants — p=0.0033
Phase 2 N=98 Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
Lung Cancer
Primary: Incidence of AE Grade 3 or Higher Toxicity — 24; 26 Participants
N/A N=104 Trajectory of Recovery in the Elderly
Delayed Emergence From Anesthesia · Postoperative Delirium · Postoperative Cognitive Dysfunction
Primary: Number of Participants Recovered on Postoperative Quality of Recovery Scale (PQRS) — 3; 5; 1; 3 Participants
Phase 2 N=84 CHOCOlate MeLatonin for AdolescenT MigrainE
Migraine
Primary: Change in Mean Visual Analog Scale (VAS) Score — -2.3; -2.7 cm
Phase 1 N=51 Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
Malignant Neoplasm of Breast
Primary: Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer — 3; 0 Participants
N/A N=39 Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth — 2.05; 3.33 mm^3
N/A N=72 Efficacy of a Health Belief Model Based Intervention for Anticoagulation Adherence
Anticoagulants
Primary: The Short-form Adherence to Refills and Medications Scale (ARMS) — 9.6; 9.4; 8.5; 9.3 score on a scale